Tag Archives: Canada grants interim authorization to COVID-19 drug

Canada has granted interim authorization to Eli Lilly’s antibody drug for treating COVID-19 in patients who are not hospitalized, but are at risk of serious illness because of their age or other conditions, the drugmaker said on Friday. The news comes weeks after the treatment, bamlanivimab, was given U.S. emergency use authorization (EUA) by the Food and Drug Administration for …

Read More »